Medical reviews find that most drugs targeting pulmonary arterial hypertension do not have adequate clinical benefits for COPD patients with comorbid pulmonary hypertension (PH). A recent systematic review titled “Treatment of pulmonary hypertension associated with COPD” published in ERJ Open Res., re-emphasised that the presence of PH in patients with COPD is associated with adverse outcomes, including increased mortality. Severe PH and resulting right ventricular failure are also associated with more severe dyspnea and limited exercise capacity, the study reported. The research, which analysed more than 4500 studies, of which 8 were focused at supplemental long-term oxygen therapy (LTOT), also affirmed the guidelines that call for supplemental LTOT in hypoxemic patients as significantly effective